Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

BACKGROUND: Survival outcomes for patients with glioblastoma remain poor, particularly for patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter. This phase II, randomized, open-label, multicenter trial investigated the efficacy and safety of 2 dose regimens of the...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Neuro Oncol
Κύριοι συγγραφείς: Nabors, L. Burt, Fink, Karen L., Mikkelsen, Tom, Grujicic, Danica, Tarnawski, Rafal, Nam, Do Hyun, Mazurkiewicz, Maria, Salacz, Michael, Ashby, Lynn, Zagonel, Vittorina, Depenni, Roberta, Perry, James R., Hicking, Christine, Picard, Martin, Hegi, Monika E., Lhermitte, Benoit, Reardon, David A.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2015
Θέματα:
Clinical Investigations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482861/
https://ncbi.nlm.nih.gov/pubmed/25762461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou356
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια